Anika Gets Bounce from Order Timing in OA Pain Business

Anika Therapeutics reported 1Q22 orthopedic sales of $34.9 million, +10.6% vs. 1Q21.

The growth came primarily from favorable order timing in the company's OA pain management line. Given the quarter-to-quarter choppiness in ordering, Anika still expects low single-digit growth for the full year in this business.

The company's other segments...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us